Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say

For the quarter ended December 2024, Ardelyx (ARDX) reported revenue of $116.13 million, up 238% over the same period last year. EPS came in at $0.02, compared to -$0.12 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $111.19 million, representing a surprise of +4.45%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.02.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Ardelyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product sales, net: $111 million versus $108.24 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +263% change. Product sales- IBSRELA: $53.84 million compared to the $50.51 million average estimate based on six analysts. Product sales- XPHOZAH: $57.16 million compared to the $57.74 million average estimate based on six analysts. Revenues- Product supply: $4.19 million versus the three-analyst average estimate of $3.67 million. The reported number represents a year-over-year change of +446%. Revenues- Licensing: $0.02 million versus the two-analyst average estimate of $0.03 million. The reported number represents a year-over-year change of -99.3%. View all Key Company Metrics for Ardelyx here>>>Shares of Ardelyx have returned +25.9% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ardelyx, Inc. (ARDX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks